AVTX Quote, Financials, Valuation and Earnings

Oragenics, Inc. has a net margin of -18405.73% compared to Avalo Therapeutics, Inc.'s net margin of --. Avalo Therapeutics, Inc.'s return on equity of -105.25% beat Oragenics, Inc.'s return on equity of -509.23%.

Avalo Therapeutics, Inc. has a consensus price target of $33.71, signalling upside risk potential of 87.82%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 131.36%. Given that Oragenics, Inc. has higher upside potential than Avalo Therapeutics, Inc., analysts believe Oragenics, Inc. is more attractive than Avalo Therapeutics, Inc..

Avalo Therapeutics, Inc. has a beta of 0.839, which suggesting that the stock is 16.057% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.

Avalo Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avalo Therapeutics, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.

Avalo Therapeutics, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Avalo Therapeutics, Inc.'s net income of -$30.6M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, Avalo Therapeutics, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avalo Therapeutics, Inc. is 1,070.86x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -18405.73% compared to Avalo Therapeutics, Inc.'s net margin of --. Avalo Therapeutics, Inc.'s return on equity of -105.25% beat Palatin Technologies's return on equity of --.

Avalo Therapeutics, Inc. has a consensus price target of $33.71, signalling upside risk potential of 87.82%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Avalo Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Avalo Therapeutics, Inc..

Avalo Therapeutics, Inc. has a beta of 0.839, which suggesting that the stock is 16.057% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Avalo Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avalo Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Avalo Therapeutics, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Avalo Therapeutics, Inc.'s net income of -$30.6M is higher than Palatin Technologies's net income of --. Notably, Avalo Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avalo Therapeutics, Inc. is 1,070.86x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Rocket Pharmaceuticals, Inc. has a net margin of -18405.73% compared to Avalo Therapeutics, Inc.'s net margin of --. Avalo Therapeutics, Inc.'s return on equity of -105.25% beat Rocket Pharmaceuticals, Inc.'s return on equity of -64.31%.

Avalo Therapeutics, Inc. has a consensus price target of $33.71, signalling upside risk potential of 87.82%. On the other hand Rocket Pharmaceuticals, Inc. has an analysts' consensus of $7.95 which suggests that it could grow by 138.16%. Given that Rocket Pharmaceuticals, Inc. has higher upside potential than Avalo Therapeutics, Inc., analysts believe Rocket Pharmaceuticals, Inc. is more attractive than Avalo Therapeutics, Inc..

Avalo Therapeutics, Inc. has a beta of 0.839, which suggesting that the stock is 16.057% less volatile than S&P 500. In comparison Rocket Pharmaceuticals, Inc. has a beta of 0.656, suggesting its less volatile than the S&P 500 by 34.373%.

Avalo Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rocket Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avalo Therapeutics, Inc. pays -- of its earnings as a dividend. Rocket Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Avalo Therapeutics, Inc. quarterly revenues are --, which are smaller than Rocket Pharmaceuticals, Inc. quarterly revenues of --. Avalo Therapeutics, Inc.'s net income of -$30.6M is higher than Rocket Pharmaceuticals, Inc.'s net income of -$50.3M. Notably, Avalo Therapeutics, Inc.'s price-to-earnings ratio is -- while Rocket Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avalo Therapeutics, Inc. is 1,070.86x versus -- for Rocket Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -18405.73% compared to Avalo Therapeutics, Inc.'s net margin of --. Avalo Therapeutics, Inc.'s return on equity of -105.25% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Avalo Therapeutics, Inc. has a consensus price target of $33.71, signalling upside risk potential of 87.82%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3398.25%. Given that Theriva Biologics, Inc. has higher upside potential than Avalo Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Avalo Therapeutics, Inc..

Avalo Therapeutics, Inc. has a beta of 0.839, which suggesting that the stock is 16.057% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

Avalo Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avalo Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Avalo Therapeutics, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Avalo Therapeutics, Inc.'s net income of -$30.6M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Avalo Therapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avalo Therapeutics, Inc. is 1,070.86x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.